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Abstract
Background: The purpose of this study was to evaluate the safety of administering high-dose daptomycin (HDD; > 6 mg/kg
actual body weight) as a 2-minute intravenous (IV) push (IVP) compared to traditional 30-minute IV piggyback (IVPB) infusion.
Methods: Retrospective cohort study comparing patients receiving HDD as an IVP or IVPB infusion. The primary outcome
was the proportion of patients with a documented infusion-related reaction (IRR) to daptomycin.
Results: Three hundred patients were included in the final analysis, 200 patients received IVP, and 100 patients received
IVPB representing a total of 1697 administrations. Median (IQR) daptomycin dose was IVP 700 mg (550-900) and IVPB 700
mg (600-900), with mg/kg doses of 8.2 (7.9-10) and 8.3 (8-10), respectively. After adjudication, IRR occurred in 1% of subjects
in each treatment group.
Conclusions: This study provides data in more than 1100 administrations of HDD administered via IVP. Infusion-related
reactions were documented in 1% of patients regardless of infusion method, suggesting comparable safety to traditional
infusion methods. This practice may be useful during fluid shortage and in the outpatient setting.
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Background
In the setting of drug shortages, hospitals and health systems
must adapt to best fulfill patient’s health care needs.1,2
Experts recommend drug shortage response strategies
including utilizing therapeutic and administration alternatives.3 Intravenous fluid shortages are especially problematic
because they impact all medications given by intravenous
infusion. Changing administration of medications traditionally administered diluted in IV base solutions to IV push
(IVP) helps conserve IV base solution for medications that
must be administered via a diluted infusion.
Safety data support 2-minute infusions of IV daptomycin
up to the labeled dose of 6 mg/kg. The pharmacokinetic
exposure and tolerability was similar between patients
receiving a 2-minute infusion of daptomycin compared to
the traditional 30-minute infusion.4,5 However, high-dose
daptomycin (HDD), defined as doses greater than 6 mg/kg
actual body weight, have been associated with improved
outcomes in both invasive staphylococcal and enterococcal
infections.6-8 Case reports describe infusion-related reactions (IRR) with administering daptomycin rapid IV infusion using a 6 mg/kg dose.9 This data raise the question if
administering off-label dosing as an IVP carries a different
safety profile.

At our institution, daptomycin was transitioned to IVP
administration in fall 2017. Intravenous push daptomycin
was administered via syringe by nursing staff over at least 2
minutes without an IV syringe pump. The purpose of this
study was to evaluate the safety of administering HDD as a
2-minute IV push (IVP) compared to traditional 30-minute
IV piggyback (IVPB) infusion.

Methods
The present study was an institutional review board (IRB)approved, retrospective cohort study in a 5-hospital health
system. Patients were identified through the electronic medical record if they received daptomycin doses greater than 6
mg/kg actual body weight and were admitted during January
9, 2017 to January 9, 2018. Patients receiving HDD as an
IVP diluted in sterile water for injection were compared to
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Table 1. Baseline Characteristics.
Baseline characteristics

Rapid infusion, n = 200

Female, n (%)
Age, median (IQR), years
Actual body weight, median (IQR), kg
BMI, median (IQR), kg/m2
Dialysis, n (%)
At baselinea
During admission
CLcr (non-HD patients), median (IQR), mL/min

Traditional infusion, n = 100

99 (50)
61 (49-71)
83 (68-102)
28 (23-35)

35 (35)
63 (52-74)
78 (68-104)
27 (23-32)

25 (13)
42 (21)
94 (54-165)

22 (22)
30 (30)
98 (55-138)

Note. IQR = interquartile range; BMI = body mass index; CLcr = estimated creatinine clearance (Cockcroft-Gault equation); HD = hemodialysis.
a
P < .05.

patients receiving an IVPB diluted in 50 mL of normal
saline.4 Doses were administered in the IVP group by nurses
without syringe pumps, while the IVPB were administered
using automated IV pumps. All daptomycin IVPB and IVP
were prepared in the central pharmacy using sterile compounding techniques. Patients were included if they received
at least 2 doses of daptomycin during their inpatient admission. Patients were excluded if they were pregnant, less than
18 years of age, or received amphotericin B or a monoclonal
antibody infusion during the index admission.
Characteristics of patient receiving HDD were collected
from the electronic medical record using a standardized data
collection instrument. The primary endpoint was the proportion of patients with documented infusion-related reactions
(IRRs) in the IVP and IVPB groups. Infusion-related reactions were assessed by the investigator based on nursing
documentation, medication administration record documentation, and documentation by health care providers in the
medical record meeting any of the following symptoms:
Skin reaction, shortness of breath, fever, hypotension, hypertension, chills, pain at infusion site, puritis, or flushing. A
maximum of 10 administrations per patient were assessed.
Any patient with a potential IRR was assessed and scored
using the Naranjo algorithm.10 All identified IRRs were adjudicated blinded to administration method by 2 clinical pharmacy specialists.
The secondary safety outcome was the proportion of
patients who had creatinine phosphokinase (CPK) elevations
or musculoskeletal-related adverse reactions. Creatinine
phosphokinase elevations were defined as follows: if CPK
was below the upper limit normal (ULN) on baseline, 2 levels >2 times ULN or 1 level >5 times ULN; if baseline CPK
is above ULN, 2 levels >5 times ULN.11 Musculoskeletal
adverse reactions were evaluated through documentation in
the medical record.
Baseline characteristics were analyzed using descriptive
statistics including median (interquartile range [IQR]) or
mean (standard deviation [SD]) for continuous data following non-parametric or parametric distribution as appropriate.
Continuous data were compared using the Mann-Whitney U

test or Student t test, as appropriate. Nominal data were
described with absolute count (percentage) and compared
using the chi-squared test or Fisher exact test.
Given the expected uncommon event rate, a 2-step sample size calculation was used to first evaluate what percent
prevalence could be detected with the given data. To estimate
a sample size to generate a 95% confidence interval (Z =
1.96) for patients experiencing an IRR, with 2% margin of
error, a sample size of 700 patients would be necessary.
Including 500 patients in each arm would allow the detection
of a 5% difference between the 2 infusion strategies with an
alpha level of 0.05 and 80% power.

Results
Three hundred patients were included in the final analysis,
200 patients receiving IVP and 100 patients receiving IVPB
representing a total of 1697 administrations. Baseline characteristics are reported in Table 1 and were similar between
groups, except the IVPB group had significantly more
patients on hemodialysis at baseline. Descriptions of daptomycin administration and IRR are reported in Table 2.
Median (IQR) daptomycin doses were IVP 700 mg (550900) and IVPB 700 mg (600-900), with mg/kg doses of 8.2
(7.9-10) and 8.3 (8-10), respectively. Administration site was
similar in both groups with the most common being central
venous catheters (IVP 99 [50%] subjects vs IVPB 48 [48%]
subjects). Peripheral administration occurred in 85 (43%)
and 48 (48%) subjects, respectively. Potential IRR occurred
in 8 (4%) of the IVP arm and 1 (1%) of IVPB arm (P = .28).
After blinded adjudication, IRR occurred in 1% of subjects
in each treatment group. Infusion-related reactions consisted
of the following reactions each in one patient of IVP group:
fever and shortness of breath. The IRR in the IVPB group
was a skin reaction. One patient from the IVPB group had
daptomycin discontinued due to an IRR compared to zero in
the IVP group. Creatinine phosphokinase levels were available for 104 (35%) patients. Elevated CPK levels occurred in
6 (5.8%) patients. No patients had documented musculoskeletal adverse reactions.
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Table 2. Daptomycin Administration Characteristics and Infusion-Related Reactions.

Daptomycin dosing and administration
Daptomycin dose, median (IQR), mg
Daptomycin dose, median (IQR), mg/kg
Daptomycin doses evaluated/total doses administered
Adjudicated infusion-related reactions, n (%)
Any reaction
  Fever
  SOB
  Skin reaction
Naranjo algorithm, score
  Doubtful, 0
  Possible, 1-4
  Probable, 5-8
  Definite ≥9
Musculoskeletal reactions, n (%)
Evaluable CPK levels, n
CPK elevations, n (%)

Rapid infusion (IVP)

Traditional infusion (IVPB)

700 (550-900)
8.2 (7.9-10)
1176/1547

700 (600-900)
8.3 (8-10)
521/690

2 (1)
1 (50)
1 (50)
0

1 (1)
0
0
1 (100)

0
1 (50)
1 (50)
0

0
0
1 (100)
0

53
4 (8)

51
2 (4)

Note. IVP = IV push; IVPB = IV piggyback infusion; IQR = interquartile range; SOB = shortness of breath; CPK = creatinine phosphokinase.

Discussion
In our experience with 200 patients who received HDD as an
IVP, we identified 2 likely IRRs representing 1% of patients.
This safety profile appears to be consistent with the 1% of
the population with IRRs in the IVPB group. Elevated CPK
levels occurred in 5.8% of the total cohort. We suggest that
IVP administration may be a reasonable approach during
fluid shortages.3 Although all patients included were inpatient, our safety evaluation of HDD as an IVP could have
implications for outpatient parenteral administration.
IVP administration of daptomycin in adult patients is supported by the U.S. Food and Drug Administration (FDA)approved package insert.4 This approval is based on safety
and pharmacokinetic data comparing 2-minute vs 30-minute
infusion up to the FDA-approved dose of 6 mg/kg.4 Twenty
patients received daptomycin via a 2-minute infusion (12
patients 6 mg/kg, 8 patients 4 mg/kg) and no IRRs were
reported.4 This study was limited by small sample size and
only included on-label dosing. A case report previously
described erythroderma developing 2 hours after the first 650
mg dose (6 mg/kg) of daptomycin given as a 2-minute infusion.9 The reaction included redness and warmth around the
face next and upper back 2 hours after the infusion. On further administration, erythroderma did not recur.9 Cervera and
colleagues described their experience with outpatient daptomycin therapy in 54 patients across 12 hospitals in Spain.
Eighteen patients received daptomycin via a 2-minute bolus
with a median administered dose of 4.67 mg/kg. No patients
in the 2-minute infusion developed phlebitis during therapy,
supporting this administration method.12 Our study adds
pragmatic data in 200 patients receiving daptomycin IVP
exclusively using greater than 6 mg/kg doses.

The present study is not without limitations. It was underpowered to evaluate a difference in IRR between IVP and
IVPB due to uncommon event rate. A case-control study
would be more statistically efficient to evaluate such an
uncommon adverse event; however, there was not a reliable
method to identify cases from the electronic medical record
as most IRRs were documented in free text nursing documentation. Attempts were made to overcome this by including all eligible patients receiving IVP daptomycin during the
study timeframe in the final analysis. There may be practice
differences in the documentation of IRRs between health
care providers that can result in information bias and subjective interpretation. We attempted to minimize this bias by
applying a validated adverse effect assessment tool to evaluate the likelihood of causality between administration and
adverse event. Additionally, infusion reactions were adjudicated by 2 clinical pharmacy specialists blinded to study
group. Our institution does not use syringe infusion pumps
for administration. Nurses administered all IVP doses by
hand with the administration instructions of more than 2
minutes; however, the actual duration of administration was
unable to be measured. Medication safety literature supports
that providers who administer IVP medication without a
watch or timer are prone to administer medications at a faster
rate than recommended.13
This study provides data in more than 1100 administrations of HDD administered via IVP. Infusion-related reactions were documented in 1% of patients. These results
support the practice of IVP daptomycin as a safe alternative
to traditional infusion. This method may be useful during
fluid shortage and in the outpatient setting.
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